Control_Liver_vs_Treatment_Liver

Profile details

Identifier: MTBLS5005_0001_00000001
Linked study: MTBLS5005 — DT-109 ameliorates nonalcoholic steatohepatitis in nonhuman primates
Comparison: Control_Liver vs Treatment_Liver
Group A: Control group for liver samples treated with H20 (vehicle).. Provides baseline data for liver tissue to compare against treatment effects.
Group B: Treatment group for liver samples treated with DT-109 (compound).. Evaluates the effect of DT-109 on liver tissue, providing insights into its therapeutic potential.
Total features tested: 34
Significant features: 34
p-value threshold: 0.05
Ratio threshold (upper): 1.5
Ratio threshold (lower): 1/1.5
Date created: 2025-09-26 00:00:00

Metabolite ID (InChI Key)	Name	Direction	Ratio	p-value
IFCXODPCRNYZJX-LJUYVFDDSA-N	[(2R)-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-[hydroxy-[(5R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropyl] (Z)-docos-11-enoate	up	71.22	0.0449
BYPUSJHQPRFYGB-UHFFFAOYSA-N	2-[3,4-bis(2-hydroxyethoxy)phenyl]-3,5-dihydroxy-7-(2-hydroxyethoxy)chromen-4-one	up	8.022	0.00352
ONPXCLZMBSJLSP-UHFFFAOYSA-N	4-hydroxy-1-(pyrrolidine-2-carbonyl)pyrrolidine-2-carboxylic acid	up	14.3	0.0136
XHHOHZPNYFQJKL-UHFFFAOYSA-N	γ-Glu-Phe	up	6.523	0.00913
PQAACQBDHKVCSF-ZJGVIXKBSA-O	(E,2S,10S)-2,10-diamino-5-[1-[(5S)-5-amino-5-carboxypentyl]-3,5-bis[(3S)-3-amino-3-carboxypropyl]pyridin-1-ium-2-yl]undec-5-enedioic acid	up	4.495	0.00344
AHYHTSYNOHNUSH-HXFGRODQSA-N	(2<i>S</i>,3a<i>R</i>,7a<i>S</i>)-1-((<i>S</i>)-<em>N</em>-((<i>S</i>)-1-carboxy-3-phenylpropyl)alanyl)hexahydro-2-indolinecarboxylic acid	up	7.391	0.0152
IFZCAKDVWKLKEK-RPBOFIJWSA-N	(2S)-2-amino-3-[[(2R)-3-henicosanoyloxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxypropanoic acid	up	4.859	0.00584
HJYYPODYNSCCOU-ODRIEIDWSA-N	Rifocin	up	4.373	0.00435
OKXWJISJKQKUTN-OAQYLSRUSA-N	1-<em>O</em>-hexadecyl-2-lyso-<em>sn</em>-glycero-3-phosphoethanolamine	up	4.952	0.00878
LTERDCBCHFKFRI-BGKMTWLOSA-N	(±)-11-HDoHE	down	0.0966	0.0395